Findings

What do systematic reviews say?

25 questions · 25 findings · 3 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 28%GRADE not reported 0 · 0%Very low 3 · 12%Low 6 · 24%Moderate 9 · 36%High 0 · 0%

Tetracycline vs placebo

HRQOL ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tetracycline vs placebo

Participant‐assessed improvement in rosacea severity · Participants with rosacea

Tetracycline showed no clear difference in participant‐assessed improvement in rosacea severity compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
RR 1.48 [0.85, 2.57]
1 study · 39 participants
Moderate

Tetracycline vs placebo

Proportion of participants with adverse event · Participants with rosacea

Tetracycline showed no clear difference in proportion of participants with adverse event compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
RR 0.95 [0.06, 14.13]
1 study · 39 participants
Moderate

Tetracycline vs placebo

Physician‐assessed improvement in rosacea severity · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 107 participants
Moderate

Tetracycline vs placebo

Assessment of erythema or telangiectasia · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Moderate

Tetracycline vs placebo

Lesion count · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Moderate

Tetracycline vs placebo

Time needed until improvement of the skin lesions · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tetracycline vs placebo

Duration of remission ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral tetracycline vs topical clindamycin

Participant global assessment VAS Visual analogue scale (VAS) (0 to 100 mm) · participants with hidradenitis suppurativa

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Oral tetracycline vs topical clindamycin

Pain VAS VAS (0 to 100 mm) · participants with hidradenitis suppurativa

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Oral tetracycline vs topical clindamycin

Nodules score Nodule count · participants with hidradenitis suppurativa

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Oral tetracycline vs topical clindamycin

Abscesses score Abscess count · participants with hidradenitis suppurativa

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Oral tetracycline vs topical clindamycin

Physician global assessment VAS VAS (0 to 100 mm) · participants with hidradenitis suppurativa

1 finding from 1 review

Interventions for hidradenitis suppurativa 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Nicotinamide plus tetracycline vs prednisone

Disease control: complete response at 8 weeks: excluding dropouts · bullous pemphigoid

It is very uncertain whether nicotinamide plus tetracycline changes disease control: complete response at 8 weeks: excluding dropouts compared with prednisone (very low certainty).

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
RR 2.5 [0.37, 16.89]
1 study · 18 participants
Very low

Nicotinamide plus tetracycline vs prednisone

Mortality at 6 months · bullous pemphigoid

It is very uncertain whether nicotinamide plus tetracycline changes mortality at 6 months compared with prednisone (very low certainty).

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
RR 0.18 [0.01, 3.85]
1 study · 18 participants
Very low

Nicotinamide plus tetracycline vs prednisone

Quality of life ‐ not measured · bullous pemphigoid

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nicotinamide plus tetracycline vs prednisone

Adverse events at 1 year · bullous pemphigoid

1 finding from 1 review

Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Topical metronidazole vs oral (oxy)tetracycline

HRQOL ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical metronidazole vs oral (oxy)tetracycline

Participant‐assessed improvement in rosacea severity · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 182 participants
Moderate

Topical metronidazole vs oral (oxy)tetracycline

Proportion of participants with adverse event · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 258 participants
Moderate